1. 1) EAU Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and Cis). 17-30, 2014. http//www.uroweb.org/gls/pdf/05%20Non-muscle%20Invasive%20BC_TaT1_LR.pdf
2. 2) Guideline for the management of nonmusclue invasive bladder cancer: (Stages Ta, T1 and Tis): 2007 update. 11-12, 2007. http://www.auanet.org/common/pdf/education/clinical-guidance/Bladder-Cancer.pdf
3. 3) NCCN Clinical Practice Guidelines in Oncology, Bladder cancer. Version 2, 40-42, 2014. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
4. 4) Sylvester RJ, Van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and Kurth K: Predicting recurrence and progression in using EORTCrisk tables: A combined analysis of 2596 patients from seven EORTC traials. Eur Urol, 49, 466-477, 2006.
5. 5) Dalbagni G, Kaag M, Cronin A, Vora K, Bochner B, Donat SM and Herr HW: Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma. Br J Urol Int., 106, 1502-1507, 2010.